Effect of bodyweight on VerifyNow Aspirin platelet function test: a retrospective review

Sandler, Melissa; Hoang, Cuong; Mak, Hannah; Levitt, Michael R.

doi:10.1136/neurintsurg-2020-016842

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results suggest increased body weight is independently associated with impaired response to low‐dose aspirin. However, the relationship was not observed in patients who took 300–325 mg of aspirin 15 . In clinical outcome‐observed studies, previous randomized trials 16 have shown that low‐dose (75–100 mg) aspirin in reducing the risks of vascular events and cancer was modified by body weight.…”

Section: Resultsmentioning

confidence: 97%

“…However, the relationship was not observed in patients who took 300-325 mg of aspirin. 15 In clinical outcome-observed studies, previous randomized trials 16 have shown that low-dose (75-100 mg) aspirin in reducing the risks of vascular events and cancer was modified by body weight. And patients taking weight-based aspirin may have a reduced incidence of venous thromboembolism following primary total joint arthroplasty.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients

Wang

Zhu

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objectives Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life‐threatening in the secondary prevention of stroke or transient ischemic attack. The aim of this study was to evaluate risk factors for bleeding adverse reaction of aspirin in ischemic stroke or transient ischemic attack. Methods This retrospective analysis included patients treated with aspirin (100 mg) as a secondary prevention for ischemic stroke or transient ischemic attack. The bleeding events that occurred during the first year were collected, including gastrointestinal, skin, nasal cavity, gum, and urinary tract bleeding events. Then, univariate and multivariate logistic regression analyses were used to identify independent factors associated with bleeding events of aspirin. Results and discussion A total of 578 patients were enrolled in this study, and 58 patients developed bleeding during the first year of secondary prevention. Body weight and combination with selective serotonin reuptake inhibitors were found to be significant risk factors for overall bleeding (p = 0.025 and 0.012). Body weight below 60 kg was a risk factor for overall bleeding and gastrointestinal bleeding events. What is new and conclusion Patients weighing less than 60 kg were at increased risk of bleeding with 100 mg aspirin for secondary prevention of cerebral infarction transient ischemic attack.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients

Wang

Zhu

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

show abstract

“…In addition, the efficacy of ticagrelor may be decreased in patients treated with higher aspirin doses (≥300 mg daily) compared with lower aspirin doses (≤100 mg daily) 14. Two NIS studies reported percentages of subtherapeutic VerifyNow aspirin results with daily aspirin doses of 325 mg15 and 81 mg16 that were in a similar range (16.2% and 13.5%, respectively).…”

Section: Discussionmentioning

confidence: 99%

Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey

Caroff

Aubert

Lavenu‐Bombled

et al. 2022

J NeuroIntervent Surg

View full text Add to dashboard Cite

BackgroundNeurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity in antithrombotic use between centers. Through a nationwide survey, we aimed to obtain an exhaustive cross-sectional overview of antithrombotic use in neurointerventional procedures in France.MethodsIn April 2021, French neurointerventional surgery centers were invited to participate in a nationwide 51-question survey disseminated through an active trainee-led research collaborative network (the JENI-RC).ResultsAll 40 centers answered the survey. Fifty-one percent of centers reported using ticagrelor and 43% used clopidogrel as premedication before intracranial stenting. For flow diversion treatment, dual antiplatelet therapy was maintained for 3 or 6 months in 39% and 53% of centers, respectively, and aspirin was prescribed for 12 months or more than 12 months in 63% and 26% of centers, respectively. For unruptured aneurysms, the most common heparin bolus dose was 50 IU/kg (59%), and only 35% of centers monitored heparin activity for dose adjustment. Tirofiban was used in 64% of centers to treat thromboembolic complications. Fifteen percent of these comprehensive stroke centers reported using tenecteplase to treat acute ischemic strokes. Cangrelor appeared as an emergent drug in specific indications.ConclusionThis nationwide survey highlights the important heterogeneity in clinical practices across centers. There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field.

show abstract

Active management of the target P2Y12 reaction unit range in patients undergoing stent-assisted coil embolization for unruptured cerebral aneurysms

Nakagawa

Park

Kotsugi

et al. 2021

J NeuroIntervent Surg

View full text Add to dashboard Cite

BackgroundPlatelet function tests have been increasingly adopted to measure patient responses to antiplatelet drugs, and to predict complications. However, no established optimal antiplatelet management for stent-assisted coil embolization (SAC) have been established. The purpose of the present study was to investigate the efficacy and feasibility of clopidogrel dose adjustment for active target P2Y12 reaction unit (PRU).MethodsA total of 202 consecutive patients undergoing SAC to treat unruptured intracranial aneurysms were prospectively recruited. All patients were given two antiplatelet agents starting 7 days prior to the procedure, and platelet function was measured with the VerifyNow test. Clopidogrel hyper-responsive patients received reduced dosing according to the values of follow-up PRUs before and 7, 14, 30, and 90 days after the procedure. Patients were divided into three groups according to clopidogrel responsiveness before treatment, and clinical outcomes and time in target PRU ranges (TTR) were analyzed.ResultsNo delayed ischemic or hemorrhagic events occurred that were associated with out-of-range PRU. PRU values in the hypo-responsive and hyper-responsive groups significantly improved 7 days after treatment with active target PRU management (p=0.05,<0.001, respectively). PRU values were controlled within the target PRU range with drug adjustment (p=0.034), and the time in TTR for all patients was 97% (4.8%–100%), which showed the feasibility of optimal control of PRU values with the protocol.ConclusionActive target PRU management can achieve control of optimal PRU values and may decrease perioperative ischemic and hemorrhagic events among patients undergoing SAC.

show abstract

Effect of bodyweight on VerifyNow Aspirin platelet function test: a retrospective review

Cited by 4 publications

References 7 publications

Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients

Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients

Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey

Active management of the target P2Y12 reaction unit range in patients undergoing stent-assisted coil embolization for unruptured cerebral aneurysms

Contact Info

Product

Resources

About